Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Elusys Therapeutics
Develops antibody-based therapies to treat infectious diseases.
Pine Brook, NJ
Contact:
Ron Eastman
Formerly Known As: E-Site Therapeutics
Acquisition
Acquired by: NightHawk Biosciences
Related News
Elusys Therapeutics’ Anthrax Drug Gains FDA Approval in Adults and Children
Elusys Therapeutics Receives First Delivery Order from US Government for Anthim
Elusys Awarded Additional $16 Million To Complete Development of Lyophilized Form of Anthim
Elusys Therapeutics Presents Efficacy Results and Other Key Findings on ETI-204 Anthrax Anti-Toxin
Elusys Awarded Additional $14.5Million Under Existing US Government Contracts
Elusys Awarded Additional $50.2 Million Under Existing U.S. Government Contract To Support ETI-204
Elusys Awarded $68 Million Contract To Develop Anthim For Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection